What is Belzutifan? 2023 [Slides]  Kidney Cancer Breakthroughs Rana McKay, MD - Synopsis below extracted from the video transcript

We're gonna start with kidney cancer and go through Belzutifan, Relatlimab, SRF-388 and the others that are listed here. Then we'll go into. And finally urothelial cancer. This is gonna  be a little bit of a whirlwind,  splash on each of these drugs where they're at.

And then  tie it all up at the end. So we'll start with kidney cancer and first we'll talk about Belzutifan. and it's, I have to say it's been amazing taking care of kidney cancer patients and seeing the evolution of the treatment of this disease over the last decade because all of the drugs that we have to treat kidney cancer, We're based on Nobel prize level work, which is pretty quite remarkable so we all know that in states of hypoxia or pseudo hypoxia, where a vhl is mutated, h accumulates in the cell and actually results in angiogenesis and proliferation. and, Belzutifan is a small molecule inhibitor of, H two Alpha. These are the data from the LITESPARK-001 – Phase 1  trial.

This was a trial that was conducted in heavily pretreated clear cell RCC patients. There were 55 patients that were enrolled on the trial. The median number of lines of prior therapy was three, and you could see that the objective response rate was 25%. The progression-free survival. 14.5 months, and there's currently a large Phase 3 that's looking at the role of Belzutifan in the refractory setting in RCC... (click here for the rest of the transcript and video).